Nothing Special   »   [go: up one dir, main page]

HK1251592A1 - Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly - Google Patents

Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly

Info

Publication number
HK1251592A1
HK1251592A1 HK18111105.9A HK18111105A HK1251592A1 HK 1251592 A1 HK1251592 A1 HK 1251592A1 HK 18111105 A HK18111105 A HK 18111105A HK 1251592 A1 HK1251592 A1 HK 1251592A1
Authority
HK
Hong Kong
Prior art keywords
antigen
binding
molecule capable
binding molecule
molecules repeatedly
Prior art date
Application number
HK18111105.9A
Other languages
Chinese (zh)
Inventor
井川智之
石井慎也
舩木美步
廣庭奈緒香
前田敦彥
根津淳一
類家慶直
馬場威
清水駿
Original Assignee
中外制藥株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中外制藥株式會社 filed Critical 中外制藥株式會社
Publication of HK1251592A1 publication Critical patent/HK1251592A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/5375—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
HK18111105.9A 2010-11-30 2013-12-05 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly HK1251592A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010266121 2010-11-30
JP2011217886 2011-09-30

Publications (1)

Publication Number Publication Date
HK1251592A1 true HK1251592A1 (en) 2019-02-01

Family

ID=46171919

Family Applications (2)

Application Number Title Priority Date Filing Date
HK19100448.7A HK1258068A1 (en) 2010-11-30 2013-12-05 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
HK18111105.9A HK1251592A1 (en) 2010-11-30 2013-12-05 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK19100448.7A HK1258068A1 (en) 2010-11-30 2013-12-05 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly

Country Status (14)

Country Link
US (3) US20140234340A1 (en)
EP (2) EP2647706B1 (en)
JP (6) JP6030452B2 (en)
KR (2) KR102568454B1 (en)
CN (3) CN103328632A (en)
AU (1) AU2011337704B2 (en)
BR (1) BR112013013354A2 (en)
CA (1) CA2819356C (en)
HK (2) HK1258068A1 (en)
MX (2) MX365235B (en)
RU (3) RU2642318C2 (en)
SG (2) SG190727A1 (en)
TW (5) TWI761912B (en)
WO (1) WO2012073992A1 (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101479381B (en) 2006-03-31 2015-04-29 中外制药株式会社 Method for control of blood kinetics of antibody
JP5484060B2 (en) 2007-09-26 2014-05-07 中外製薬株式会社 Antibody constant region variants
AU2008304778B9 (en) 2007-09-26 2014-05-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
PT2275443E (en) 2008-04-11 2016-03-15 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
CN103328632A (en) 2010-11-30 2013-09-25 中外制药株式会社 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP3604330A1 (en) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
JP5997151B2 (en) 2011-06-30 2016-09-28 中外製薬株式会社 Heterodimerized polypeptide
CN107287660A (en) * 2011-09-30 2017-10-24 中外制药株式会社 Ion concentration dependence binding molecule library
TW201817745A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
WO2013047748A1 (en) 2011-09-30 2013-04-04 中外製薬株式会社 Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
EP2752200B1 (en) * 2011-09-30 2023-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule inducing immune response to target antigen
JP6271251B2 (en) * 2011-10-05 2018-01-31 中外製薬株式会社 An antigen-binding molecule that promotes elimination of an antigen containing a sugar chain receptor-binding domain from plasma
CN113416256A (en) * 2011-11-30 2021-09-21 中外制药株式会社 Drug comprising transporter (carrier) that enters into cell to form immune complex
KR102475951B1 (en) 2012-02-24 2022-12-08 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB
MX2014014678A (en) 2012-05-30 2015-02-10 Chugai Pharmaceutical Co Ltd Target-tissue-specific antigen-binding molecule.
EP3892638A1 (en) * 2012-05-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
JP6280300B2 (en) * 2012-08-24 2018-02-14 中外製薬株式会社 Brain disease treatment
CN104736706B (en) 2012-08-24 2021-10-19 中外制药株式会社 Fc gamma RIIb specific Fc region variants
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
TWI693073B (en) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 Therapeutic agent for GPC3 target is the effective therapeutic agent for GPC3 target administered to patients
WO2015097928A1 (en) * 2013-12-24 2015-07-02 中外製薬株式会社 Method for measuring soluble gpc3 protein
KR102249779B1 (en) 2012-12-27 2021-05-07 추가이 세이야쿠 가부시키가이샤 Heterodimerized polypeptide
KR102065112B1 (en) * 2013-02-28 2020-01-10 삼성전자주식회사 A method to screen antibodies with high selectivity
JP6598680B2 (en) 2013-04-02 2019-10-30 中外製薬株式会社 Fc region variant
PT3050896T (en) 2013-09-27 2021-08-24 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
WO2015083764A1 (en) 2013-12-04 2015-06-11 中外製薬株式会社 Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
JP6827319B2 (en) 2014-05-08 2021-02-10 中外製薬株式会社 GPC3 targeted therapies GPC3 targeted therapies administered to patients for whom therapy is effective
KR101624702B1 (en) 2014-08-01 2016-05-27 한국과학기술원 Novel polypeptide binding with human complement component 5a and Uses Thereof
PL3233921T3 (en) 2014-12-19 2022-01-10 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
KR20180054923A (en) 2014-12-19 2018-05-24 추가이 세이야쿠 가부시키가이샤 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3247723A1 (en) * 2015-01-22 2017-11-29 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
CN114773469A (en) 2015-02-05 2022-07-22 中外制药株式会社 Antibodies comprising an ion concentration-dependent antigen-binding domain, FC region variants, IL-8-binding antibodies and uses thereof
KR101892883B1 (en) 2015-02-27 2018-10-05 추가이 세이야쿠 가부시키가이샤 Composition for treating il-6-related diseases
US11376326B2 (en) 2015-07-01 2022-07-05 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
CA2996635A1 (en) * 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
KR20230079500A (en) 2015-09-18 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8-binding antibodies and uses thereof
EP3733698A1 (en) 2015-09-23 2020-11-04 Bristol-Myers Squibb Company Glypican-3 binding fibronectin based scafflold molecules
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN109310755A (en) * 2016-02-02 2019-02-05 卡德门企业有限公司 The bispecific binding protein of PD-L1 and KDR
BR112019001989A2 (en) 2016-08-02 2019-08-20 Visterra Inc engineered polypeptides and uses thereof
AU2017305073B2 (en) 2016-08-05 2024-02-01 Chugai Seiyaku Kabushiki Kaisha Composition for prevention or treatment of IL-8 related diseases
JP7178342B2 (en) 2016-08-12 2022-11-25 ヤンセン バイオテツク，インコーポレーテツド Engineered Antibodies with Enhanced Agonism and Effector Functions, and Other Fc Domain-Containing Molecules
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP7191833B2 (en) 2017-01-30 2022-12-19 中外製薬株式会社 Anti-sclerostin antibodies and uses thereof
WO2018178076A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
AU2018255938A1 (en) 2017-04-21 2019-10-31 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
WO2018203545A1 (en) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
CA3065171A1 (en) * 2017-06-05 2018-12-13 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical ch2-ch3 region mutations
SI3658184T1 (en) 2017-07-27 2024-01-31 Alexion Pharmaceuticals, Inc., High concentration anti-c5 antibody formulations
AU2018338451A1 (en) * 2017-09-25 2020-04-02 University Of Florida Research Foundation, Incorporated Immunoassays for detection of RAN proteins
JP7518764B2 (en) 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド Dosage and Administration of Anti-C5 Antibodies for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
WO2019087115A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CN111556895B (en) 2017-11-14 2024-09-13 中外制药株式会社 Anti-C1S antibodies and methods of use
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
BR112021002037A2 (en) 2018-08-10 2021-05-04 Chugai Seiyaku Kabushiki Kaisha anti-cd137 antigen binding molecule and its use
CN109374884B (en) * 2018-12-24 2021-10-22 四川沃文特生物技术有限公司 PCT concentration detection kit and preparation method thereof
US20220153875A1 (en) 2019-03-19 2022-05-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
WO2020209318A1 (en) 2019-04-10 2020-10-15 中外製薬株式会社 Method for purifying fc region-modified antibody
CN110467672B (en) * 2019-08-20 2020-05-05 江苏省疾病预防控制中心(江苏省公共卫生研究院) Fully human monoclonal neutralizing antibody aiming at SFTSV and application thereof
BR112022012010A2 (en) 2019-12-18 2022-08-30 Hoffmann La Roche ANTIBODIES, ISOLATED NUCLEIC ACID, HOST CELL, PHARMACEUTICAL FORMULATION, USE OF THE ANTIBODY, METHOD OF PRODUCTION OF AN ANTIBODY, METHOD OF TREATMENT OF AN INDIVIDUAL THAT HAS CANCER, AND METHOD OF TREATMENT OF AN INDIVIDUAL THAT HAS AN INFLAMMATORY OR AUTOIMMUNE DISEASE
AU2019479791B2 (en) 2019-12-27 2024-05-02 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
TW202144395A (en) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 Anti-CD137 antigen-binding molecule for use in cancer treatment
WO2022015934A2 (en) * 2020-07-15 2022-01-20 The Johns Hopkins Universtiy Comprehensive analysis of anti-allergen antibodies using phage display
US20230416371A1 (en) 2020-08-28 2023-12-28 Chugai Seiyaku Kabushiki Kaisha Heterodimer fc polypeptide
WO2022155340A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
AR125344A1 (en) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd ANTI-C1S ANTIBODY
WO2022235960A1 (en) * 2021-05-06 2022-11-10 Sorrento Therapeutics, Inc. Neutralizing antibodies that bind variant sars-cov-2 spike proteins
CA3221735A1 (en) 2021-06-18 2022-12-22 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
BR112023022992A2 (en) 2021-06-25 2024-01-23 Chugai Pharmaceutical Co Ltd ANTI-CTLA-4 ANTIBODY
AU2022297107B2 (en) 2021-06-25 2024-08-01 Chugai Seiyaku Kabushiki Kaisha Use of anti-ctla-4 antibody
CN113563480B (en) * 2021-07-12 2023-04-28 成都维瑾柏鳌生物医药科技有限公司 CLD protein mutant and application thereof
WO2023013618A1 (en) * 2021-08-02 2023-02-09 国立研究開発法人国立長寿医療研究センター Human astrovirus infection receptor and application of same
CN115873111B (en) * 2022-12-19 2024-06-07 华润生物医药有限公司 CLDN18.2 antibody and application thereof

Family Cites Families (493)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4961501U (en) 1972-09-06 1974-05-30
JPS525973Y2 (en) 1973-09-06 1977-02-08
FR2416931A1 (en) 1978-02-10 1979-09-07 Lambiotte Usines NON-POLLUTING WOOD CARBONIZATION PROCESS
US4769320A (en) 1982-07-27 1988-09-06 New England Medical Center Hospitals, Inc. Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations
US4738927A (en) 1982-03-31 1988-04-19 Ajinomoto Co. Inc. Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell
ES8404858A1 (en) 1982-04-12 1984-05-16 Hybritech Inc Method of affinity purification employing monoclonal antibodies.
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6088703U (en) 1983-11-24 1985-06-18 リョービ株式会社 Cutting waste discharge device for automatic planing machine
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH06104071B2 (en) * 1986-08-24 1994-12-21 財団法人化学及血清療法研究所 Factor IX Monoclonal antibody specific for conformation
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
JPH01144991A (en) 1987-12-02 1989-06-07 Kagaku Oyobi Ketsusei Riyouhou Kenkyusho Purification of blood coagulation factor viii
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
IL91778A (en) 1988-09-28 1994-10-07 Lilly Co Eli Method fo rthe reduction of heterogeneity of monoclonal antibodies
US5126250A (en) 1988-09-28 1992-06-30 Eli Lilly And Company Method for the reduction of heterogeneity of monoclonal antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5202253A (en) * 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
CA2006684C (en) 1988-12-30 1996-12-17 Charles T. Esmon Monoclonal antibody against protein c
JPH0636741B2 (en) * 1989-11-08 1994-05-18 帝人株式会社 Method for separating human protein C
DE69130561T2 (en) 1990-02-16 1999-06-24 Boston Biomedical Research Institute, Inc., Boston, Mass. Hybrid reagents with the ability to selectively release molecules into cells
US5130129A (en) 1990-03-06 1992-07-14 The Regents Of The University Of California Method for enhancing antibody transport through capillary barriers
ATE185601T1 (en) 1990-07-10 1999-10-15 Cambridge Antibody Tech METHOD FOR PRODUCING SPECIFIC BONDING PAIRS
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0546073T3 (en) 1990-08-29 1998-02-02 Genpharm Int Production and use of transgenic, non-human animals capable of forming heterologous antibodies
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5468634A (en) 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
ATE181571T1 (en) 1991-09-23 1999-07-15 Medical Res Council METHODS FOR PRODUCING HUMANIZED ANTIBODIES
PT1024191E (en) 1991-12-02 2008-12-22 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
BR9204244A (en) 1992-10-26 1994-05-03 Cofap Gray cast iron
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
JPH08503617A (en) 1992-12-01 1996-04-23 プロテイン デザイン ラブズ、インコーポレーテッド Humanized antibody reactive with L-selectin
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
WO1994021681A1 (en) 1993-03-19 1994-09-29 Johns Hopkins University School Of Medicine Growth differentiation factor-8
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
EP0710288B1 (en) 1993-06-10 2006-04-05 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
GB9314271D0 (en) 1993-07-09 1993-08-18 Inst Of Cancer The Research Cell growth factor receptors
FR2707189B1 (en) 1993-07-09 1995-10-13 Gradient Ass Method for treating combustion residues and installation for implementing said method.
IL107742A0 (en) 1993-11-24 1994-02-27 Yeda Res & Dev Chemically-modified binding proteins
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
DE122009000068I2 (en) 1994-06-03 2011-06-16 Ascenion Gmbh Process for the preparation of heterologous bispecific antibodies
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
MX9700312A (en) 1994-07-11 1997-07-31 Univ Texas Methods and compositions for the specific coagulation of vasculature.
TW416960B (en) 1994-07-13 2001-01-01 Chugai Pharmaceutical Co Ltd Reshaped human antibody to human interleukin-8
KR100261941B1 (en) 1994-07-13 2000-07-15 나가야마 오사무 Reconstituted human antibody against human interleukin-8
US6048972A (en) 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
JP3865418B2 (en) 1994-07-13 2007-01-10 中外製薬株式会社 Reconstituted human antibody against human interleukin-8
CN1156460A (en) 1994-07-13 1997-08-06 中外制药株式会社 Reconstructed hyman antibody against human interleukin-8
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
EP0783893B1 (en) 1994-10-07 2012-04-04 Chugai Seiyaku Kabushiki Kaisha Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient
CZ298325B6 (en) 1994-10-21 2007-08-29 Kishimoto@Tadamitsu Pharmaceutical composition intended for prevention or treatment of plasmocytosis
DE19500911A1 (en) 1995-01-13 1996-07-18 Basf Ag Substituted 2-phenylpyridines
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2304786T3 (en) 1995-04-27 2008-10-16 Amgen Fremont Inc. ANTI-IL-8 HUMAN ANTIBODIES, DERIVED FROM IMMUNIZED XENORATONES.
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5830478A (en) 1995-06-07 1998-11-03 Boston Biomedical Research Institute Method for delivering functional domains of diphtheria toxin to a cellular target
KR100259828B1 (en) 1995-09-11 2000-06-15 히라타 다다시 Antibody againsts alpha-chain of human interleukin 5 receptor
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
ZA976326B (en) 1996-07-19 1998-02-03 Amgen Inc Analogs of cationic proteins.
US7247302B1 (en) 1996-08-02 2007-07-24 Bristol-Myers Squibb Company Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
CA2262405A1 (en) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
US6025158A (en) 1997-02-21 2000-02-15 Genentech, Inc. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
KR100838862B1 (en) 1997-03-21 2008-06-16 츄가이 세이야꾸 가부시키가이샤 Preventives or remedies for sensitized T cell-related diseases containing IL-6 antagonists as the active ingredient
HU226175B1 (en) * 1997-04-17 2008-06-30 Amgen Inc Human ob protein suspension, process for producing thereof and use for production of pharmaceutical composition
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
CN1068524C (en) 1997-06-23 2001-07-18 叶庆炜 Process for preparing medicine for curing intractable psoriasis
US5980893A (en) 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
CA2296322A1 (en) 1997-08-15 1999-02-25 Chugai Seiyaku Kabushiki Kaisha Preventives and/or remedies for systemic lupus erythematosus containing anti-il-6 receptor antibody as the active ingredient
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
NZ503489A (en) 1997-10-03 2002-11-26 Chugai Pharmaceutical Co Ltd Natural humanized antibody, method of production and pharmaceutical composition
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
WO1999047140A1 (en) 1998-03-17 1999-09-23 Margolin Solomon B Topical antiseptic compositions and methods
CZ297083B6 (en) 1998-03-17 2006-09-13 Chugai Seiyaku Kabushiki Kaisha Agent for prevention and treatment of inflammatory intestinal disease containing IL-6 antagonist as active component
ES2292236T3 (en) 1998-04-02 2008-03-01 Genentech, Inc. VARIATIONS OF ANTIBODIES AND THEIR FRAGMENTS.
DK2180007T4 (en) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6475718B2 (en) * 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
JP2002531466A (en) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド Humanized antibodies to gamma interferon
JP2002534959A (en) 1998-12-08 2002-10-22 バイオベーション リミテッド Methods for modifying immunogenic proteins
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
PL220113B1 (en) 1999-01-15 2015-08-31 Genentech Inc Variant of parent polypeptide comprising the Fc region, polypeptide comprising a variant of the Fc region with altered binding affinity of Fc gamma receptor (FcγR), a polypeptide comprising the variant of Fc region with altered binding affinity of neonatal Fc receptor (FcRn), a composition, isolated nucleic acid, vector, host cell, method for preparing the polypeptide variant, the use of the polypeptide variant and method for preparing a the Fc region variant
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2006225302B2 (en) 1999-03-25 2010-08-12 AbbVie Deutschland GmbH & Co. KG Human antibodies that bind human IL-12 and methods for producing
DK2270149T3 (en) 1999-04-09 2016-05-09 Kyowa Hakko Kirin Co Ltd PROCEDURE TO CONTROL THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE.
WO2000075314A1 (en) 1999-06-02 2000-12-14 Chugai Research Institute For Molecular Medicine, Inc. Novel hemopoietin receptor protein nr10
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20040058393A1 (en) 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
HUP0301835A2 (en) 2000-05-03 2003-09-29 Mbt Munich Biotechnology Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
KR20060088905A (en) 2000-06-16 2006-08-07 휴먼 게놈 사이언시즈, 인코포레이티드 Antibodies that immunospecifically bind to blys
AU2011244851A1 (en) 2000-07-27 2011-11-24 The John Hopkins University School Of Medicine Promyostatin peptides and methods of using same
ATE448301T1 (en) 2000-09-08 2009-11-15 Univ Zuerich COLLECTION OF PROTEINS WITH REPEATING SEQUENCES (REPEAT PROTEINS) THAT CONTAIN REPETITIVE SEQUENCE MODULES
PL218428B1 (en) 2000-10-06 2014-12-31 Kyowa Hakko Kogyo Kk Cells producing antibody compositions
EP2113516B1 (en) 2000-10-10 2014-05-21 Genentech, Inc. Antibodies against C5 inhibiting type II endothelial cell activation
WO2002032925A2 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
DE60133029T2 (en) 2000-10-25 2009-03-12 Chugai Seiyaku K.K. MEANS FOR PREVENTING OR TREATING PSORIASIS WITH AN IL-6 ANTAGONIST AS AN ACTIVE AGENT
AU2000279625A1 (en) 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
GEP20074252B (en) 2001-04-13 2007-12-10 Biogen Idec Inc Antibodies to vla-1
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20040236080A1 (en) 2001-06-22 2004-11-25 Hiroyuki Aburatani Cell proliferation inhibitors containing anti-glypican 3 antibody
JP4303105B2 (en) 2001-06-28 2009-07-29 ドマンティス リミテッド Dual specific ligands and their use
WO2004058821A2 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20040161741A1 (en) 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
JP4958387B2 (en) 2001-08-17 2012-06-20 ジェネンテック， インコーポレイテッド Complement pathway inhibitors that bind to C5 and C5A without interfering with C5B formation
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US20030190705A1 (en) 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
ES2624547T3 (en) 2001-11-14 2017-07-14 Janssen Biotech, Inc. Anti il 6 antibodies, compositions, methods and uses
ES2307832T3 (en) 2001-12-03 2008-12-01 Amgen Fremont Inc. ANTIBODY CLASSIFICATION BASED ON THE CHARACTERISTICS OF UNION.
US20050171339A1 (en) 2001-12-28 2005-08-04 Izumi Sugo Method of stabilizing protein
WO2004003140A2 (en) 2002-01-18 2004-01-08 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
DK1476541T3 (en) 2002-01-18 2008-11-03 Zymogenetics Inc Cytokine (zcytor17 ligand)
AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
JP4468803B2 (en) 2002-05-31 2010-05-26 ジーイー・ヘルスケア・バイオ−サイエンシーズ・アーベー Method for coupling a binder to a substrate surface
EP1510943A4 (en) 2002-05-31 2007-05-09 Celestar Lexico Sciences Inc Interaction predicting device
AU2003242024A1 (en) 2002-06-05 2003-12-22 Chugai Seiyaku Kabushiki Kaisha Method of constructing antibody
US20060141456A1 (en) 2002-06-12 2006-06-29 Cynthia Edwards Methods and compositions for milieu-dependent binding of a targeted agent to a target
AU2003248652A1 (en) 2002-06-12 2003-12-31 Genencor International, Inc. Methods for improving a binding characteristic of a molecule
ITMI20021527A1 (en) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche C5 COMPONENT ANTIBODIES OF COMPLEMENT AND THEIR USE
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
US20050260213A1 (en) 2004-04-16 2005-11-24 Scott Koenig Fcgamma-RIIB-specific antibodies and methods of use thereof
WO2004022595A1 (en) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
ES2344734T3 (en) 2002-09-16 2010-09-06 Johns Hopkins University ACTIVATION OF MYOSTATIN BY METALOPROTEASE, AND METHODS TO MODULATE THE ACTIVITY OF MYOSTATIN.
CN101987871A (en) 2002-09-27 2011-03-23 赞科股份有限公司 Optimized fc variants and methods for their generation
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
CA2510087C (en) 2002-12-16 2018-09-04 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (il-8)
JP2006524039A (en) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド Identification and production of antibody containing mutant Fc region and use thereof
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20040223970A1 (en) 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
KR20060026004A (en) 2003-02-28 2006-03-22 안티제닉스 아이엔씨 Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
PT1601697E (en) 2003-02-28 2007-09-04 Lonza Biologics Plc Antibody purification by protein a and ion exchange chromatography
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
CN1756564A (en) 2003-03-04 2006-04-05 亚历森制药有限公司 Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
EP1606316A2 (en) 2003-03-24 2005-12-21 ZymoGenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
RU2337107C2 (en) 2003-05-02 2008-10-27 Ксенкор, Инк. OPTIMIZED Fc-VERSIONS THAT HAVE ALTERED BINDING TO FcγR AND METHODS FOR THEIR PRODUCTION
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
AU2004245025A1 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (GDF8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2004113387A2 (en) 2003-06-24 2004-12-29 Merck Patent Gmbh Tumour necrosis factor receptor molecules with reduced immunogenicity
WO2005023193A2 (en) 2003-09-04 2005-03-17 Interleukin Genetics, Inc. Methods of treating endometriosis
WO2005027966A2 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
CA2545539A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
WO2005037315A1 (en) 2003-10-17 2005-04-28 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for mesothelioma
AU2004284090A1 (en) 2003-10-24 2005-05-06 Avidia, Inc. LDL receptor class A and EGF domain monomers and multimers
EP1689777B1 (en) 2003-11-05 2007-04-25 Ares Trading S.A. Process for the purification of il-18 binding protein
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
US20050142133A1 (en) 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
EP2221315A1 (en) 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
CN1889979B (en) 2003-12-10 2012-09-19 米德列斯公司 IP-10 antibodies and their uses
AR048210A1 (en) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd A PREVENTIVE AGENT FOR VASCULITIS.
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
UA93855C2 (en) 2003-12-31 2011-03-25 Шеринг-Плау Лтд. Neutralizing epitope-based growth enhancing vaccine
EP1706424B1 (en) 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20080145367A1 (en) 2004-02-11 2008-06-19 Warner-Lambert Compay, Llc Methods of Treating Osteoarthritis with Il-6 Antagonists
JP4695133B2 (en) 2004-03-23 2011-06-08 イーライ リリー アンド カンパニー Anti-myostatin antibody
KR20070035482A (en) 2004-03-24 2007-03-30 추가이 세이야쿠 가부시키가이샤 Therapeutic agent for auris interna disorder containing il-6 antagonist as active ingredient
WO2005090405A1 (en) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha Subtype of humanized antibody against interleukin-6 receptor
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
AR048335A1 (en) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENTS FOR INTERNAL EAR DISORDERS CONTAINING AN IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
JP2008504289A (en) 2004-06-25 2008-02-14 メディミューン，インコーポレーテッド Increased production of recombinant antibodies in mammalian cells by site-directed mutagenesis
EP1774019B1 (en) 2004-07-06 2011-10-12 Bioren, Inc. Look-through mutagenesis for developing altered polypeptides with enhanced properties
DE602005024502D1 (en) 2004-07-09 2010-12-16 Chugai Pharmaceutical Co Ltd ANTI-glypican-3 ANTIBODY
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CN103172731A (en) 2004-07-15 2013-06-26 赞科股份有限公司 Optimized Fc variants
PL1776384T3 (en) 2004-08-04 2013-10-31 Mentrik Biotech Llc Variant fc regions
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2006031370A2 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
US7964706B2 (en) 2004-10-22 2011-06-21 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
EP1805320B1 (en) 2004-10-22 2014-09-03 Amgen Inc. Methods for refolding of recombinant antibodies
CN102731654A (en) 2004-10-22 2012-10-17 米迪缪尼有限公司 High affinity antibodies against hmgb1 and methods of use thereof
WO2006050166A2 (en) 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CN101098890B (en) 2004-11-12 2012-07-18 赞科股份有限公司 Fc variants with altered binding to fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8329186B2 (en) 2004-12-20 2012-12-11 Isu Abxis Co., Ltd Treatment of inflammation using BST2 inhibitor
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
AU2005318700B2 (en) 2004-12-23 2011-04-14 Novo Nordisk A/S Antibody binding affinity ligands
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
NO346624B1 (en) 2004-12-28 2022-11-07 Univ Di Genova Monoclonal antibody against NKG2A
AU2006204791A1 (en) 2005-01-12 2006-07-20 Xencor, Inc Antibodies and Fc fusion proteins with altered immunogenicity
GB0502358D0 (en) 2005-02-04 2005-03-16 Novartis Ag Organic compounds
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP1858924A1 (en) 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
JP5057967B2 (en) 2005-03-31 2012-10-24 中外製薬株式会社 sc (Fv) 2 structural isomer
TWI544076B (en) 2005-03-31 2016-08-01 Chugai Pharmaceutical Co Ltd A method of manufacturing a polypeptide that controls assembly
WO2006109592A1 (en) 2005-04-08 2006-10-19 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
EP1874820A4 (en) 2005-04-20 2010-09-22 Amgen Fremont Inc High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
EP2295466A3 (en) 2005-04-25 2011-08-17 Pfizer Inc. Antibodies to myostatin
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
UY29504A1 (en) 2005-04-29 2006-10-31 Rinat Neuroscience Corp DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME.
PE20061324A1 (en) 2005-04-29 2007-01-15 Centocor Inc ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
KR101367544B1 (en) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 Stabilizer for protein preparation comprising meglumine and use thereof
CA2652434A1 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized proteins that target ep-cam
FR2888850B1 (en) 2005-07-22 2013-01-11 Pf Medicament NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS
DK1919503T3 (en) 2005-08-10 2014-12-15 Macrogenics Inc Identification and preparation of antibodies with variant fc regions and methods of use thereof
CN103450359B (en) 2005-08-19 2018-07-24 惠氏有限责任公司 The antagonist antibodies of anti-GDF-8 and the purposes in ALS and other GDF-8- associated disorder treatments
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
KR101135220B1 (en) 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 Anti-myostatin antibodies
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
CN101330929B (en) 2005-10-14 2014-03-05 学校法人福冈大学 Inhibitor of transplanted islet dysfunction in islet transplantation
AU2006305119B2 (en) 2005-10-21 2012-12-20 Chugai Seiyaku Kabushiki Kaisha Agents for treating cardiopathy
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
AR057582A1 (en) 2005-11-15 2007-12-05 Nat Hospital Organization AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
KR20080084818A (en) 2005-11-25 2008-09-19 각고호우징 게이오기주크 Therapeutic agent for prostate cancer
SG172617A1 (en) 2005-12-12 2011-07-28 Ac Immune Sa Therapeutic vaccine
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
PL2548577T3 (en) 2005-12-29 2017-08-31 Janssen Biotech, Inc Human anti-il-23 antibodies, compositions, methods and uses
KR101345586B1 (en) 2006-01-10 2013-12-31 지모제넥틱스, 인코포레이티드 Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
AU2007208678B2 (en) 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
US20070190056A1 (en) 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
EP1992692B1 (en) 2006-02-21 2013-01-09 Protenova Co., Ltd. Immunoglobulin affinity ligand
JP4179517B2 (en) 2006-02-21 2008-11-12 プロテノバ株式会社 Immunoglobulin affinity ligand
EP2918269A1 (en) 2006-03-02 2015-09-16 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
ES2527695T3 (en) 2006-03-08 2015-01-28 Archemix Llc Complement binding aptamers and anti-C5 agents useful in the treatment of eye disorders
CA2645810C (en) 2006-03-15 2018-12-11 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP2024392A2 (en) 2006-03-17 2009-02-18 Biogen Idec MA, Inc. Stabilized polypeptide compositions
CA2644663A1 (en) 2006-03-23 2007-09-27 Kirin Pharma Kabushiki Kaisha Agonist antibody to human thrombopoietin receptor
JP2009532027A (en) 2006-03-28 2009-09-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド Anti-IGF-1R antibodies and uses thereof
CN101479381B (en) 2006-03-31 2015-04-29 中外制药株式会社 Method for control of blood kinetics of antibody
WO2007114325A1 (en) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
TWI392684B (en) 2006-04-05 2013-04-11 Abbott Biotech Ltd Antibody purification
CN101495146B (en) 2006-04-07 2012-10-17 国立大学法人大阪大学 Muscle regeneration promoter
TWI395754B (en) 2006-04-24 2013-05-11 Amgen Inc Humanized c-kit antibody
CA2652733C (en) 2006-05-25 2016-06-21 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
CN102585002A (en) 2006-06-02 2012-07-18 瑞泽恩制药公司 High affinity antibodies to human il-6 receptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
PE20080333A1 (en) 2006-06-08 2008-06-15 Chugai Pharmaceutical Co Ltd AGENTS TO PREVENT OR TREAT INFLAMMATORY DISEASES
EP2032602B1 (en) 2006-06-15 2013-03-27 The Board of Trustees of the University of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
CL2007001829A1 (en) 2006-06-23 2008-01-25 Smithkline Beecham Corp N- [4-Chloro-2-hydroxy-3- (piperazine-1-sulfonyl) phenyl] -n- (2-chloro-3-fluorophenyl) urea P-toluenesulfonate; preparation process; pharmaceutical composition; pharmaceutical combination; and use in the treatment of a disease mediated by chemokine il-8, such as asthma and epoc.
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
JP2009545322A (en) 2006-08-02 2009-12-24 ザ ユーエービー リサーチ ファウンデーション Methods and compositions relating to a defined antigen-specific soluble monoclonal variable lymphocyte receptor
AR062223A1 (en) 2006-08-09 2008-10-22 Glycart Biotechnology Ag MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE
PL2059536T3 (en) 2006-08-14 2014-07-31 Xencor Inc Optimized antibodies that target cd19
ES2404941T3 (en) 2006-09-05 2013-05-29 Eli Lilly And Company Anti-myostatin antibodies
AU2007294575B2 (en) 2006-09-08 2013-06-27 Viela Bio, Inc. Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2064240A2 (en) 2006-09-18 2009-06-03 Xencor, Inc. Optimized antibodies that target hm1.24
EP3424950A1 (en) 2006-10-06 2019-01-09 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Prevention of tissue ischemia, related methods and compositions
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
WO2008121160A2 (en) 2006-11-21 2008-10-09 Xencor, Inc. Optimized antibodies that target cd5
CN100455598C (en) 2006-11-29 2009-01-28 中国抗体制药有限公司 Antibody of anti human CD20 from human resources functionally, and application
PT2426143T (en) 2007-01-05 2017-09-22 Univ Zuerich Method of providing disease-specific binding molecules and targets
WO2008091798A2 (en) 2007-01-22 2008-07-31 Xencor, Inc. Optimized ca9 antibodies and methods of using the same
JP5357778B2 (en) 2007-01-23 2013-12-04 ゼンコー・インコーポレイテッド Optimized CD40 antibodies and methods of using the same
ES2564392T3 (en) 2007-01-23 2016-03-22 Shinshu University IL-6 inhibitors for the treatment of chronic rejection
EP2107115A1 (en) 2007-01-24 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
WO2008098115A2 (en) 2007-02-07 2008-08-14 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
EP2069404B1 (en) 2007-02-14 2011-01-05 Vaccinex, Inc. Humanized anti-cd100 antibodies
US8293883B2 (en) 2007-02-23 2012-10-23 Schering Corporation Engineered anti-IL-23P19 antibodies
WO2008114011A2 (en) 2007-03-19 2008-09-25 Medimmune Limited Fc polypeptide variants obtained by ribosome display methodology
EA018204B1 (en) 2007-03-20 2013-06-28 Эли Лилли Энд Компани Anti-sclerostin antibodies
AU2008228247A1 (en) 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
CL2008001071A1 (en) 2007-04-17 2009-05-22 Smithkline Beecham Corp Method to obtain penta-specific antibody against human il-8 / cxcl8, gro-alpha / cxcl1, gro-beta / cxcl2), gro-gamma / cxcl3 and ena-78 / cxcl5; penta-specific antibody; production process of the same; vector, hybridoma or cella that comprises it; pharmaceutical composition; use to treat copd, other diseases.
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
US20090252729A1 (en) 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
EP2708557A1 (en) 2007-05-30 2014-03-19 Xencor, Inc. Method and compositions for inhibiting CD32B expressing cells
WO2008145141A1 (en) 2007-05-31 2008-12-04 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
PT2164961E (en) 2007-06-25 2015-04-08 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
US20090074780A1 (en) 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
EP3543691A1 (en) 2007-06-29 2019-09-25 Quest Diagnostics Investments Incorporated Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry
US20100129355A1 (en) 2007-07-26 2010-05-27 Osaka University Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
US20110105724A1 (en) 2007-08-16 2011-05-05 Stephanie Jane Clegg Novel compounds
JP2010537985A (en) 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド Anti-IGF-1R antibodies and uses thereof
CA2697922A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
EP2031064A1 (en) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Method for increasing protein titres
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
WO2009041734A1 (en) 2007-09-26 2009-04-02 Kyowa Hakko Kirin Co., Ltd. Agonistic antibody against human thrombopoietin receptor
AU2008304778B9 (en) 2007-09-26 2014-05-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
JP5484060B2 (en) 2007-09-26 2014-05-07 中外製薬株式会社 Antibody constant region variants
TWI578998B (en) 2007-09-26 2017-04-21 中外製藥股份有限公司 Anti-il-6 receptor antibody
EP2617736A1 (en) * 2007-09-28 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having improved kinetics in plasma
KR101601986B1 (en) 2007-10-02 2016-03-17 추가이 세이야쿠 가부시키가이샤 Remedy for graft-versus-host disease comprising interleukin-6 receptor inhibitor as the active ingredient
KR100888133B1 (en) 2007-10-02 2009-03-13 에스케이에너지 주식회사 Method of preparing multicomponent bismuth molybdate catalysts comprising four metal components and method of preparing 1,3-butadiene using said catalysts
AR068767A1 (en) 2007-10-12 2009-12-02 Novartis Ag ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN
US20100249381A1 (en) 2007-10-22 2010-09-30 David Delvaille Method for Purifying FC-Fusion Proteins
PE20091163A1 (en) 2007-11-01 2009-08-09 Wyeth Corp ANTIBODIES FOR GDF8
TW200936160A (en) 2007-11-15 2009-09-01 Chugai Pharmaceutical Co Ltd Monoclonal antibodies that bind to anexelekto and uses thereof
MY162546A (en) 2007-12-05 2017-06-15 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
MX337081B (en) 2007-12-05 2016-02-10 Chugai Pharmaceutical Co Ltd Anti-nr10 antibody and use thereof.
AU2008343855B2 (en) 2007-12-21 2013-08-15 Amgen Inc. Anti-amyloid antibodies and uses thereof
CA2958185C (en) 2007-12-26 2020-08-25 Xencor, Inc. Fc variants with altered binding to fcrn
US8426141B2 (en) 2008-01-18 2013-04-23 Stichting Sanquin Bloedvoorziening Methods for increasing the therapeutic efficacy of immunoglobulin G class 3 (IgG3) antibodies
EP2238156B1 (en) 2008-01-29 2014-10-01 Ablynx N.V. Methods to stabilize proteins and polypeptides
AU2015227424A1 (en) 2008-04-11 2015-10-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
PT2275443E (en) 2008-04-11 2016-03-15 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP2303311B1 (en) 2008-05-14 2018-08-01 Agriculture Victoria Services Pty Ltd Angiogenin for use in treating skeletal muscle disorders
US20110081347A1 (en) 2008-06-04 2011-04-07 Macrogenics, Inc. Antibodies with Altered Binding to FcRn and Methods of Using Same
KR101665729B1 (en) 2008-06-05 2016-10-12 국립연구개발법인 고쿠리츠간켄큐센터 Neuroinvasion inhibitor
AU2009279197B2 (en) 2008-08-05 2013-12-12 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
LT2853545T (en) 2008-09-17 2016-09-26 Xencor Inc. Antibody specific for IgE
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5028372B2 (en) 2008-09-26 2012-09-19 京セラドキュメントソリューションズ株式会社 Image processing apparatus, image processing method, and image processing program
JP5229888B2 (en) 2008-09-30 2013-07-03 独立行政法人産業技術総合研究所 Protein A mutant protein and antibody capture agent with improved easy dissociation in weakly acidic region
MX2011004001A (en) 2008-10-14 2011-05-19 Genentech Inc Immunoglobulin variants and uses thereof.
HRP20230167T1 (en) 2008-11-10 2023-03-31 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
JP5807300B2 (en) 2008-11-18 2015-11-10 株式会社シノテスト Method and reagent for measuring C-reactive protein in sample
AU2009323002B2 (en) 2008-11-25 2016-01-28 Vitaeris Inc. Antagonists of IL-6 to raise albumin and/or lower CRP
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
AU2010203353B2 (en) 2009-01-12 2016-06-16 Cytomx Therapeutics, Inc Modified antibody compositions, methods of making and using thereof
CN102369291A (en) 2009-01-23 2012-03-07 比奥根艾迪克Ma公司 Stabilized Fc polypeptides with reduced effector function and methods of use
WO2010098863A1 (en) 2009-02-26 2010-09-02 Lpath, Inc. Humanized platelet activating factor antibody design using anti-lipid antibody templates
JP5717624B2 (en) 2009-03-19 2015-05-13 中外製薬株式会社 Antibody constant region variants
TWI646193B (en) 2009-03-19 2019-01-01 中外製藥股份有限公司 Antibody constant region alteration
SG10201900451SA (en) 2009-03-19 2019-02-27 Chugai Pharmaceutical Co Ltd Pharmaceutical formulation containing improved antibody molecules
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
AU2010201495B2 (en) 2009-04-16 2012-04-12 Accenture Global Services Limited Touchpoint customization system
SG176074A1 (en) 2009-05-15 2011-12-29 Chugai Pharmaceutical Co Ltd Anti-axl antibody
EP2435079A4 (en) 2009-05-26 2012-11-14 Univ Johns Hopkins Novel desmin phosphorylation sites useful in diagnosis and intervention of cardiac disease
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US20110002931A1 (en) 2009-06-23 2011-01-06 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
US8945511B2 (en) 2009-06-25 2015-02-03 Paul Weinberger Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3
MX2011014008A (en) 2009-06-26 2012-06-01 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format.
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
KR101790802B1 (en) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 Anti-gitr antibodies
WO2011037158A1 (en) 2009-09-24 2011-03-31 中外製薬株式会社 Modified antibody constant regions
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
NZ599148A (en) 2009-10-06 2014-08-29 Medimmune Ltd Rsv-specific binding molecule
US9096877B2 (en) 2009-10-07 2015-08-04 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
JP6095368B2 (en) 2009-10-27 2017-03-15 ユセベ ファルマ ソシエテ アノニム Nav1.7 antibody whose function is modified
CN101875696B (en) 2009-11-11 2012-02-08 中国人民解放军军事医学科学院生物工程研究所 Antibody, and preparation method and application thereof
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
CA2785414C (en) 2009-12-25 2019-01-22 Tomoyuki Igawa Polypeptide modification method for purifying polypeptide multimers
CN102971342B (en) 2010-01-28 2016-08-03 Ab生物科学公司 The new antibodies that affinity reduces and the method preparing described antibody
US20120315267A1 (en) 2010-02-09 2012-12-13 Glaxosmithkline Llc Novel uses
SI2536745T1 (en) 2010-02-19 2016-10-28 Xencor Inc. Novel ctla4-ig immunoadhesins
AU2011223866B2 (en) 2010-03-01 2015-05-21 Alexion Pharmaceuticals Inc. Methods and compositions for treating Degos' disease
WO2011108714A1 (en) 2010-03-04 2011-09-09 中外製薬株式会社 Antibody constant region variant
JP2011184418A (en) 2010-03-11 2011-09-22 Tokyo Institute Of Technology Affinity variable antibody
PE20130393A1 (en) 2010-03-11 2013-04-07 Rinat Neuroscience Corp ANTIBODIES WITH PH-DEPENDENT ANTIGEN UNION
TW201206466A (en) 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding
TWI667346B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
CN104402997A (en) 2010-04-30 2015-03-11 阿雷克森制药公司 Antibodies having reduced immunogenicity in a human
JO3340B1 (en) 2010-05-26 2019-03-13 Regeneron Pharma Antibodies to human gdf8
WO2011149046A1 (en) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター Therapeutic agent for pancreatic cancer
AR081556A1 (en) 2010-06-03 2012-10-03 Glaxo Group Ltd HUMANIZED ANTIGEN UNION PROTEINS
WO2012016227A2 (en) 2010-07-29 2012-02-02 Xencor, Inc. Antibodies with modified isoelectric points
CN103221426B (en) 2010-08-16 2016-01-13 安姆根公司 In conjunction with the antibody of myostatin, composition and method
CN103201293B (en) 2010-09-08 2016-04-27 哈洛齐梅公司 The method of assessment and qualification or development condition active therapeutic protein
CN103261222B (en) 2010-09-10 2017-07-28 医疗免疫有限公司 Antibody derivatives
EP2638067A2 (en) 2010-11-08 2013-09-18 Genentech, Inc. Subcutaneously administered anti-il-6 receptor antibody
CN103328632A (en) 2010-11-30 2013-09-25 中外制药株式会社 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2012088247A2 (en) 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments
EP3539991A1 (en) 2011-01-07 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
WO2012132067A1 (en) 2011-03-30 2012-10-04 中外製薬株式会社 Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
EP3604330A1 (en) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
EA201391248A1 (en) 2011-03-01 2014-05-30 Эмджен Инк. BISPECIFIC BINDING AGENTS
EP2698431B1 (en) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
EP3404041B1 (en) 2011-04-19 2020-07-22 Amgen Inc. Method for treating osteoporosis
ES2709654T3 (en) 2011-04-29 2019-04-17 Apexigen Inc Anti-CD40 antibodies and methods of use
MX361175B (en) 2011-05-04 2018-11-29 Omeros Corp Compositions for inhibiting masp-2 dependent complement acitivation.
LT2714733T (en) 2011-05-21 2019-06-10 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
CA2839986A1 (en) 2011-06-20 2012-12-27 St. Louis University Targeting the neuromuscular junction for treatment
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. Antibody variants and uses thereof
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
EP2752200B1 (en) 2011-09-30 2023-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule inducing immune response to target antigen
RU2014117505A (en) 2011-09-30 2015-11-10 Чугаи Сейяку Кабусики Кайся ANTIGEN-BINDING MOLECULE FOR ACCELERATION OF REMOVAL OF ANTIGENS
TW201817745A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
WO2013047748A1 (en) 2011-09-30 2013-04-04 中外製薬株式会社 Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CN107287660A (en) 2011-09-30 2017-10-24 中外制药株式会社 Ion concentration dependence binding molecule library
JP6271251B2 (en) 2011-10-05 2018-01-31 中外製薬株式会社 An antigen-binding molecule that promotes elimination of an antigen containing a sugar chain receptor-binding domain from plasma
CN113416256A (en) * 2011-11-30 2021-09-21 中外制药株式会社 Drug comprising transporter (carrier) that enters into cell to form immune complex
KR102475951B1 (en) 2012-02-24 2022-12-08 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB
KR102494534B1 (en) 2012-03-14 2023-02-06 리제너론 파마슈티칼스 인코포레이티드 Multispecific antigen-binding molecules and uses thereof
EP2825037B1 (en) 2012-03-16 2019-05-01 Regeneron Pharmaceuticals, Inc. Rodents expressing ph-sensitive immunoglobulin sequences
MX355732B (en) 2012-03-16 2018-04-27 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same.
HUE037613T2 (en) 2012-03-29 2018-09-28 Novimmune Sa Anti-tlr4 antibodies and uses thereof
TWI619729B (en) 2012-04-02 2018-04-01 再生元醫藥公司 Anti-hla-b*27 antibodies and uses thereof
JP6211597B2 (en) 2012-05-01 2017-10-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ New antibody
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP3892638A1 (en) 2012-05-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
MX2014014678A (en) 2012-05-30 2015-02-10 Chugai Pharmaceutical Co Ltd Target-tissue-specific antigen-binding molecule.
SA113340642B1 (en) 2012-06-15 2015-09-15 فايزر إنك Improved antagonist antibodies against GDF-8 and uses therefor
JP6514103B2 (en) 2012-07-06 2019-05-15 ゲンマブ ビー．ブイ． Dimer protein with triple mutation
KR20150041662A (en) 2012-08-13 2015-04-16 리제너론 파아마슈티컬스, 인크. Anti-pcsk9 antibodies with ph-dependent binding characteristics
CN104736706B (en) 2012-08-24 2021-10-19 中外制药株式会社 Fc gamma RIIb specific Fc region variants
US9133269B2 (en) 2012-08-24 2015-09-15 Anaptysbio, Inc. Humanized antibodies directed against complement protein C5
TW201922795A (en) 2012-09-10 2019-06-16 愛爾蘭商尼歐托普生物科學公司 Anti-MCAM antibodies and associated methods of use
IL270110B (en) 2012-09-13 2022-08-01 Bristol Myers Squibb Co Fibronectin based scaffold domain proteins that bind to myostatin
TW201418707A (en) 2012-09-21 2014-05-16 Alexion Pharma Inc Screening assays for complement component C5 antagonists
JP2016500704A (en) 2012-11-06 2016-01-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． Compositions and methods for modulating cell signaling
ES2791183T3 (en) 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anti-GDF15 antibodies
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
BR112015017619A2 (en) 2013-01-24 2017-11-21 Glaxosmithkline Ip Dev Ltd liquid formulation, use of a formulation, and kit
AU2014213147B2 (en) 2013-01-31 2019-01-17 lmmunAbs Inc. C5 antibody and method for preventing and treating complement-related diseases
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
WO2014144080A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
CA2906835A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Myostatin antagonism in human subjects
US9321686B2 (en) 2013-03-15 2016-04-26 Forta Corporation Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP2951203B1 (en) 2013-03-15 2019-05-22 Xencor, Inc. Heterodimeric proteins
EP2970508A4 (en) 2013-03-15 2016-12-14 Permeon Biologics Inc Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
ES2768648T3 (en) 2013-03-29 2020-06-23 Alexion Pharma Inc Compositions and methods for increasing serum half-life of a complement C5-targeted therapeutic agent
JP6598680B2 (en) 2013-04-02 2019-10-30 中外製薬株式会社 Fc region variant
EP3816625A1 (en) 2013-05-06 2021-05-05 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP2997042B1 (en) 2013-05-17 2019-08-07 Centre National de la Recherche Scientifique (CNRS) Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
BR112015029788B1 (en) 2013-05-31 2024-01-02 Zymeworks Inc HETERO-MULTIMER, USE AND METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND METHOD FOR REDUCING EFFECTOR FUNCTION OF AN IgG FC CONSTRUCT
EP3406633B1 (en) 2013-07-25 2022-03-02 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
TN2016000057A1 (en) 2013-08-14 2017-07-05 Novartis Ag Methods of treating sporadic inclusion body myositis
CA2920293A1 (en) 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
WO2015034000A1 (en) 2013-09-04 2015-03-12 プロテノバ株式会社 Immunoglobulin-binding domain multimer
EP2853898B1 (en) 2013-09-27 2017-01-04 Medizinische Hochschule Hannover Analysis of myostatin in serum
BR112016010706A2 (en) 2013-12-20 2017-12-05 Hoffmann La Roche bispecific antibody, pharmaceutical composition, use of bispecific antibody, nucleic acid sequence, expression vector, host cell and method of producing an antibody
US20170248609A1 (en) 2014-01-27 2017-08-31 Novartis Ag Biomarkers predictive of muscle atrophy, method and use
CA3177696A1 (en) 2014-02-20 2015-08-27 Allergan, Inc. Complement component c5 antibodies
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
TW201622746A (en) 2014-04-24 2016-07-01 諾華公司 Methods of improving or accelerating physical recovery after surgery for hip fracture
JP7037885B2 (en) 2014-06-30 2022-03-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-TNFa antibody showing pH-dependent antigen binding
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
WO2016073879A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
TW201627007A (en) 2014-12-08 2016-08-01 諾華公司 MYOSTATIN or ACTIVIN antagonists for the treatment of sarcopenia
PL3233921T3 (en) 2014-12-19 2022-01-10 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
KR20180054923A (en) 2014-12-19 2018-05-24 추가이 세이야쿠 가부시키가이샤 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3247723A1 (en) 2015-01-22 2017-11-29 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
CN114773469A (en) 2015-02-05 2022-07-22 中外制药株式会社 Antibodies comprising an ion concentration-dependent antigen-binding domain, FC region variants, IL-8-binding antibodies and uses thereof
KR101892883B1 (en) 2015-02-27 2018-10-05 추가이 세이야쿠 가부시키가이샤 Composition for treating il-6-related diseases
US20190135903A1 (en) 2015-03-31 2019-05-09 Alexion Pharmaceuticals, Inc. Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
CA2982810A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
WO2016178980A1 (en) 2015-05-01 2016-11-10 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
JP2018520139A (en) 2015-06-26 2018-07-26 アレクシオン ファーマシューティカルズ， インコーポレイテッド Methods for treating patients according to vaccination with eculizumab or eculizumab variants
US10940126B2 (en) 2015-07-03 2021-03-09 Camilla Svensson Inhibition of IL-8 in the treatment of pain and/or bone loss
CN113896789A (en) 2015-09-15 2022-01-07 供石公司 Anti-pro/latent myostatin antibodies and uses thereof
KR20230079500A (en) 2015-09-18 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8-binding antibodies and uses thereof
TW201718014A (en) 2015-10-12 2017-06-01 諾華公司 Use of C5 inhibitors in Transplant Associated Microangiopathy
AR107077A1 (en) 2015-12-18 2018-03-21 Chugai Pharmaceutical Co Ltd ANTI-C5 ANTIBODIES AND METHODS FOR USE
CN108473562B (en) 2015-12-18 2022-06-17 中外制药株式会社 Anti-myostatin antibodies, polypeptides comprising variant FC regions, and methods of use
US10233252B2 (en) 2015-12-21 2019-03-19 Wisconsin Alumni Research Foundation pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR20180094110A (en) 2016-01-08 2018-08-22 스칼러 락, 인크. Anti-pro / latent myostatin antibodies and methods of use thereof
WO2017123636A1 (en) 2016-01-11 2017-07-20 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
EP3408291A1 (en) 2016-01-25 2018-12-05 Shire Human Genetic Therapies, Inc. Anti-c5 antibodies with enhanced ph switch
KR20230169484A (en) 2016-06-13 2023-12-15 스칼러 락, 인크. Use of myostatin inhibitors and combination therapies
FI3468990T3 (en) 2016-06-14 2024-06-26 Regeneron Pharma Anti-c5 antibodies and uses thereof
KR102306744B1 (en) 2016-06-17 2021-09-28 추가이 세이야쿠 가부시키가이샤 Anti-myostatin antibodies and methods of use
MX2018015030A (en) 2016-06-17 2019-04-22 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use.
AU2017305073B2 (en) 2016-08-05 2024-02-01 Chugai Seiyaku Kabushiki Kaisha Composition for prevention or treatment of IL-8 related diseases
JP7191833B2 (en) 2017-01-30 2022-12-19 中外製薬株式会社 Anti-sclerostin antibodies and uses thereof
BR112019015426A2 (en) 2017-01-31 2020-05-26 Chugai Seiyaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION FOR USE IN TREATING OR PREVENTING A C5-RELATED DISEASE AND A METHOD FOR TREATING OR PREVENTING A C5-RELATED DISEASE
KR20240151866A (en) 2017-03-14 2024-10-18 파이브 프라임 테라퓨틱스, 인크. Antibodies binding to vista at acidic ph
UA125757C2 (en) 2017-03-16 2022-06-01 Медімм'Юн Лімітед Anti-par2 antibodies and uses thereof
PL3411400T3 (en) 2017-04-03 2021-12-20 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity
JP7518764B2 (en) 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド Dosage and Administration of Anti-C5 Antibodies for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
KR20200095485A (en) 2017-12-04 2020-08-10 라 파마슈티컬스 인코포레이티드 Regulators of complement activity
KR20210038697A (en) 2018-08-01 2021-04-07 추가이 세이야쿠 가부시키가이샤 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
WO2020209318A1 (en) 2019-04-10 2020-10-15 中外製薬株式会社 Method for purifying fc region-modified antibody

Also Published As

Publication number Publication date
JP7096863B2 (en) 2022-07-06
AU2011337704B2 (en) 2017-06-15
EP2647706B1 (en) 2023-05-17
CA2819356A1 (en) 2012-06-07
CA2819356C (en) 2023-01-24
MX2013006109A (en) 2014-01-31
EP4231014A3 (en) 2024-08-14
TWI654204B (en) 2019-03-21
JP2019048842A (en) 2019-03-28
KR102385507B1 (en) 2022-04-12
JP6030452B2 (en) 2016-11-24
SG190727A1 (en) 2013-07-31
TWI705072B (en) 2020-09-21
MX2019001726A (en) 2019-07-18
JP6431506B2 (en) 2018-11-28
JP2017019773A (en) 2017-01-26
TWI812066B (en) 2023-08-11
RU2018121428A3 (en) 2019-12-09
KR102568454B1 (en) 2023-08-18
TWI654203B (en) 2019-03-21
TW201920260A (en) 2019-06-01
JPWO2012073992A1 (en) 2014-05-19
EP2647706A4 (en) 2015-04-22
TW201249871A (en) 2012-12-16
US11891434B2 (en) 2024-02-06
TW202225189A (en) 2022-07-01
JP2020189850A (en) 2020-11-26
TW202043266A (en) 2020-12-01
AU2011337704A1 (en) 2013-07-04
EP4231014A2 (en) 2023-08-23
TW201730217A (en) 2017-09-01
JP2022105222A (en) 2022-07-12
CN107973851A (en) 2018-05-01
CN108715614A (en) 2018-10-30
US20140234340A1 (en) 2014-08-21
EP2647706A1 (en) 2013-10-09
JP6745858B2 (en) 2020-08-26
RU2642318C2 (en) 2018-01-24
HK1258068A1 (en) 2019-11-01
JP7497388B2 (en) 2024-06-10
KR20130121900A (en) 2013-11-06
MX365235B (en) 2019-05-28
RU2658504C9 (en) 2018-08-21
BR112013013354A2 (en) 2020-10-06
WO2012073992A1 (en) 2012-06-07
SG10201509790YA (en) 2015-12-30
TWI761912B (en) 2022-04-21
RU2757786C2 (en) 2021-10-21
JP2024109896A (en) 2024-08-14
US20240158482A1 (en) 2024-05-16
RU2013129815A (en) 2015-01-10
US20180258161A1 (en) 2018-09-13
KR20220045258A (en) 2022-04-12
RU2658504C1 (en) 2018-06-21
RU2018121428A (en) 2019-12-09
CN103328632A (en) 2013-09-25

Similar Documents

Publication Publication Date Title
HK1251592A1 (en) Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
IL259956B (en) Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
HRP20181355T1 (en) Bispecific antigen binding molecules
IL268886A (en) Bispecific t cell activating antigen binding molecules
HK1247938A1 (en) Generation of binding molecules
IL237985B (en) Humanized immunobinder capable of binding to an antigen of interest